A critical consideration is that diabetes itself substantially increases gastroparesis riskaffecting up to 5% of patients with type 1 diabetes and 1% with type 2 diabetes
Conclusion New treatments for type 2 diabetes and obesity offer exciting opportunities to make a difference in the lives of many patients
However, it is important to note that: Clinical trials have limitations in detecting rare adverse events, particularly those that may take extended periods to develop Post-marketing surveillance continues to monitor for previously unidentified safety concerns Individual case reports may emerge, but these do not establish causation without rigorous epidemiological analysis Why the question arises : The association between Wegovy and diverticulitis may be questioned because: Gastrointestinal effects : Wegovy commonly causes GI side effects including nausea, constipation, and changes in bowel habits, which might theoretically affect colonic function
It is vital to source all metabolic compounds from verified, high-quality providers to ensure purity and safety.
They are pathway-level markers they do not predict response to tirzepatide or any specific compound, but they describe the biology into which it is prescribed